Osimertinib and Selinexor Team Up Against Aggressive T-Cell Leukemia in Preclinical Study
A preclinical study reports that the EGFR inhibitor osimertinib and the XPO1 inhibitor selinexor synergistically deplete c-MYC and trigger nucleolar ...
Tag: EGFR inhibitor
POPULAR NEWS
-
Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
-
Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast
-
ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth
-
Systematic review maps sustainability tensions in offshore wind development